Topoisomerase I and II in Germ Cell Cancer as Indicators of Possible Drug Selection for Salvage Chemotherapy Studies

2002 ◽  
pp. 99-100
Author(s):  
D. M. Berney ◽  
J. Shamash ◽  
J. Gaffney ◽  
R. T. D. Oliver
Keyword(s):  
Germ Cell ◽  
Topoisomerase I ◽  
Cell Cancer ◽  
Salvage Chemotherapy ◽  
Germ Cell Cancer ◽  
Drug Selection ◽  
Selection For

scholarly journals Salvage Chemotherapy With Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin for Relapsed Germ Cell Cancer

2018 ◽  
Vol 16 (6) ◽  
pp. 458-465.e2 ◽  
Author(s):  
Hayley S. McKenzie ◽  
Graham Mead ◽  
Robert Huddart ◽  
Jeff D. White ◽  
Gordon J.S. Rustin ◽  
...  
Keyword(s):  
Germ Cell ◽  
Cell Cancer ◽  
Salvage Chemotherapy ◽  
Germ Cell Cancer

scholarly journals Effective salvage chemotherapy with etoposide, dactinomycin, and methotrexate in refractory germ cell cancer. Australasian Germ Cell Trial Group.

1990 ◽  
Vol 8 (1) ◽  
pp. 27-32 ◽  
Author(s):  
J A Levi ◽  
D Thomson ◽  
V Harvey ◽  
G Gill ◽  
D Raghavan ◽  
...  
Keyword(s):  
Complete Remission ◽  
Germ Cell ◽  
Cell Cancer ◽  
Complete Response ◽  
Drug Regimen ◽  
Salvage Chemotherapy ◽  
Germ Cell Cancer ◽  
Severe Nausea ◽  
Residual Masses ◽  
Benign Teratoma

Fifty-one patients with advanced germ cell malignancy who had either failed to achieve complete remission with initial cisplatin, vinblastine, and bleomycin chemotherapy or who had relapsed after complete response (CR) to this therapy and then proven refractory on retreatment, were treated with etoposide (75 mg/m2 for 3 days), dactinomycin (1 mg/m2 day 1), and methotrexate (30 mg/m2 day 1) (EAM) every 3 weeks. Courses were continued until maximum response without empirical limit, and if complete remission was achieved, two courses of consolidation therapy were given before cessation of treatment. Thirteen patients (25%) were complete responders with residual masses containing fibrosis or benign teratoma being subsequently resected in seven patients. Two patients had persisting viable carcinoma within residual masses that were completely resected, leaving no evidence of disease (NED); the combined CR plus NED rate was 29%. The only pretreatment factor significantly influencing this response rate was tumor volume. Toxicities were moderate, with leukopenia being observed in 28% of patients, but it was severe in only 2%. There was one death from septicemia. Severe nausea and vomiting occurred in only 9% of patients and treatment-related stomatitis was observed in 42%. All patients achieving CR plus NED have been followed for a minimum of 5 years and no relapses have occurred, suggesting that these patients are cured. Unlike other regimens of salvage chemotherapy, this treatment program did not contain cisplatin and it is contended that a completely noncrossresistant drug regimen based on etoposide provides the opportunity to further improve the curability of patients with advanced germ cell cancer.

Salvage chemotherapy with gemcitabine plus oxaliplatin for patients with testicular germ cell cancer

2014 ◽  
Vol 19 (6) ◽  
pp. 1112-1117 ◽  
Author(s):  
Masahiro Uchida ◽  
Koji Kawai ◽  
Tomokazu Kimura ◽  
Daishi Ichioka ◽  
Ei-ichiro Takaoka ◽  
...  
Keyword(s):  
Germ Cell ◽  
Cell Cancer ◽  
Salvage Chemotherapy ◽  
Germ Cell Cancer ◽  
Testicular Germ Cell ◽  
Testicular Germ Cell Cancer

scholarly journals Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [18F]FDG PET

2002 ◽  
Vol 86 (4) ◽  
pp. 506-511 ◽  
Author(s):  
C Bokemeyer ◽  
C Kollmannsberger ◽  
K Oechsle ◽  
B M Dohmen ◽  
A Pfannenberg ◽  
...  
Keyword(s):  
Germ Cell ◽  
Treatment Response ◽  
Fdg Pet ◽  
Cell Cancer ◽  
Salvage Chemotherapy ◽  
Germ Cell Cancer ◽  
High Dose ◽  
Early Prediction ◽  
18F Fdg
Sign in / Sign up

Export Citation Format

Share Document